On Chemball

My Chemball

As Supplier

My RFQ Manage Products

As Buyer

My RFQ Post RFQ

My Account

+86-571-8627 3270

WUHAN BJM PHARMACEUTIACLS CO.,LTD

11 YRS

Hubei, China

CNY 5 Million

47952 m²

Less than 50 people

Main Products: N-Methyl-1,2-Benzenediamine Dihydrochloride / Pirfenidone / Letrozole

Hubei, China

Contact Supplier

Home Company Profile Contact Us Post Buying Request

Letrozole / CAS 112809-51-5

OVERVIEW

Packaging

25 KG/Fibre Drum

Lead Time

1-2 weeks

REQUEST A QUOTATION

Submit

Get Free Samples

Less than 1KG required

DESCRIPTION

Product Name:Letrozole

Product number:BJM-006

CAS:112809-51-5

Molecular formula:

C17H11N5

Molecular weight:285.3

Content:99.0%min

Letrozole

CAS No:112809-51-5

Alisa：4,4'-(1H-1,2,4-TRIAZOL-1-YLMETHYLENE) BIS-BENZONITRILE;FEMARA;CGS-20267;LETROZOL;LETROZOLE;LetrozoleUsp28;Letrozole99%;CGS-20267, Femara

Molecular Formula:C17H11N5

Molecular weigh:285.31

Structural formula:

Letrozole CAS No. 112809-51-5

Secification:

Items	Specification
Description	White to off white CrystallinePowder
Melting point	181°C~183°C
Water	≤0.3%
Residue on ignition	≤0.1%
Heavy metals	≤10PPM
Total Impurity(HPLC)	≤0.3%
Assay(HPLC)	98.0~102.0%

Packing: 1kg/ foil bag ; net weight 25kg/drum or according to required

Usage:antineoplastic drug,Letrozole is a new generation of selective aromatase inhibitors, for the artificial synthesis of benzyl triazole derivative, inhibit aromatase, decreased estrogen levels, thereby eliminating stimulation of estrogen on tumor growth.

Typical Properties

Letrozole is a new generation of highly selective aromatase inhibitor, which is a synthetic benzyltriazole derivative. By inhibiting aromatase, letrozole can reduce the level of estrogen, so as to eliminate the stimulating effect of estrogen on tumor growth. The in vivo activity is 150-250 times stronger than that of the first generation aromatase inhibitor amlumide. Because of its high selectivity, it does not affect the function of glucocorticoid, mineralocorticoid and thyroid. High dose use has no inhibitory effect on the secretion of adrenal corticosteroids, so it has a high therapeutic index. Preclinical studies have shown that letrozole has no potential toxicity, mutagenic and carcinogenic effects on various systems and target organs of the body, and has less toxic and side effects, good tolerance. Compared with other aromatase inhibitors and anti estrogen drugs, letrozole has stronger anti-tumor effect. It is suitable for the treatment of patients with advanced breast cancer who are not effective in the treatment of estrogen and early treatment of breast cancer.

CAS No.

112809-51-5

Formula

C17H11N5

Molecular Mass

285.3027

Exact Mass

285.10100

PSA

78.29000

Logp

2.65916

IUPAC

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile

SMILES

C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3

Matter Classification

organic

GET SAMPLE